ICON (ICLR)
(Delayed Data from NSDQ)
$214.93 USD
-0.08 (-0.04%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $216.67 +1.74 (0.81%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$214.93 USD
-0.08 (-0.04%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $216.67 +1.74 (0.81%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum C VGM
Zacks News
Why Icon PLC (ICLR) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Philips' (PHG) Diagnosis & Treatment Segment Drives Growth
by Zacks Equity Research
Philips (PHG) boosts Diagnosis & Treatment on the back of Precision Diagnosis and Image-Guided Therapy businesses and an expanding partner base.
Philips (PHG) Aids Image-Guided Treatment With New Stent System
by Zacks Equity Research
Philips (PHG) boosts its Image-Guided Therapy portfolio with the Duo Venous Stent System, strengthening its Diagnosis & Treatment segment.
ICON (ICRL) Gains From Strategic Acquisitions, Innovation
by Zacks Equity Research
In addition to its focused efforts within the biotech segment, ICON (ICLR) continues to drive forward its leadership in large pharma.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Icon PLC (ICLR) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Icon PLC (ICLR) possesses solid growth attributes, which could help it handily outperform the market.
Icon PLC (ICLR) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Icon PLC (ICLR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Icon PLC (ICLR) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Icon PLC (ICLR) Soars 4.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Icon PLC (ICLR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Do Options Traders Know Something About ICON (ICLR) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to ICON (ICLR) stock based on the movements in the options market lately.
Here's Why Investors Should Retain ICON (ICLR) Stock Now
by Zacks Equity Research
Investors remain optimistic about ICON (ICLR) due to its impressive strategic pacts and stable solvency.
Icon PLC (ICLR) Up 6.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Icon PLC (ICLR) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ICLR vs. CRL: Which Stock Is the Better Value Option?
by Zacks Equity Research
ICLR vs. CRL: Which Stock Is the Better Value Option?
ICON (ICLR) Q1 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
ICON's (ICLR) first-quarter 2024 performance is driven by its efficient service delivery and strong cost control.
Icon PLC (ICLR) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 0.87% and 0.08%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for These 4 Medical Products Stocks in Q1 Earnings?
by Zacks Equity Research
Medical Products companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how BSX, TMO, ALGN and ICLR fare this time.
ICON (ICLR) Gains From New Offerings, Strategic Acquisitions
by Zacks Equity Research
ICON (ICLR) continues to develop its collaboration and delivery models, invest in technology and enhance its project and program management capabilities.
Analysts Estimate Teladoc (TDOC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Teladoc (TDOC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Icon PLC (ICLR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ICLR or CRL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ICLR vs. CRL: Which Stock Is the Better Value Option?